Please ensure Javascript is enabled for purposes of website accessibility

Why Flexion Therapeutics Jumped 12.6% Today

By Brian Orelli, PhD – Apr 3, 2018 at 7:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was good news on the payer front.

What

Flexion Therapeutics (FLXN) jumped 12.6% today after announcing in a regulatory filing that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific Q code for Zilretta, Flexion's non-opioid sustained-release steroid injection for knee pain that was approved by the Food and Drug Administration in October.

A standing doctor examining a seated patient's knee

Image source: Getty Images.

So what

The product-specific Q code, which will go into effect on July 1, allows doctors to bill Medicare faster than when the claims have to be processed manually under a miscellaneous code that doctors currently have to use. Flexion estimates about half of the U.S. market for Zilretta will be administered to Medicare patients in doctors' offices.

Last month, Flexion got a product-specific C code for use of Zilretta by Medicare patients in hospital outpatient departments, which went into effect on April 1.

Don't discount the value of having a drug having a product-specific code. Doctors are ultimately running a business, so all things being equal, they're more likely to prescribe a drug that has a quicker reimbursement.

Now what

The ultimate CMS code is a dedicated J code, which Flexion has applied for. The list of drugs under consideration should be out by the end of this month. CMS will then hold a public hearing -- as the government is apt to do -- followed by a final list of J codes issued in the fourth quarter that will go into effect Jan. 1, 2019.

While the issuance of a product-specific Q code is a good sign that Flexion will get a dedicated J code, it's debatable whether the news is worth today's double-digit increase unless investors really thought there was a small chance of Flexion getting the code.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Flexion Therapeutics, Inc. Stock Quote
Flexion Therapeutics, Inc.
FLXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.